Medtronic and DaVita have launched Mozarc Medical, an independent company focused on kidney health and patient-centred technology solutions.
Mozarc Medical is co-owned by the two companies, with each having an equal equity stake.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This deal was first announced in 2022.
Mozarc Medical CEO Ven Manda said: “Mozarc Medical’s focus will be on meaningful and innovative kidney health technologies that improve the overall patient experience and increase access to care globally.
“At a time when patient preferences are evolving and in-home kidney care is on the rise, Mozarc Medical is uniquely positioned to better serve patients with kidney disease around the world.”
Mozarc Medical claims to have a global workforce, which includes the former Medtronic Renal Care Solutions (RCS) business along with other industry-leading talents.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn the first three quarters of the fiscal year 2023, Medtronic’s RCS business posted revenues of $64m, $63m and $70m, respectively.
DaVita group vice-president of research and development Dr Mahesh Krishnan said: “The launch of Mozarc Medical holds tremendous promise to improve the lives of patients living with kidney disease as it seeks to revolutionise the approach to home dialysis by improving accessibility, ease of use and clinical performance.
“Our investment in this venture is born from our decades-long commitment to advancing kidney care, and our aim is that it will fuel patient-centric solutions that may not have otherwise been possible.”
